JFitzgibbon
TL2 Member · Valladolid, ES
Keeps a personal log and shares the numbers when they are relevant, with the measurement caveats attached.
Joined 21 September 2025 · last posted 3d
87Posts here
1Topics
1Solutions
591Likes received
447Likes given
18Badges
159Days visited
2.3kPosts read
Recent activity
Full stream-
I joined for one answer and stayed for a year — what changed my mind Replied, post #107 · Start Here › Welcome · 25 Jul 2026 · 8 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #129 · Evidence › Journal club · 23 Jul 2026 · 28 likes SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose is not the highest available, which is the central and…
-
Documenting a supplier's response to a discrepancy Replied, post #43 · Sourcing › Vendor reports · 20 Jul 2026 · 23 likes post #42 answers the question as asked. The question underneath it is different. What "verified" means on our pages: specific lots were independently measured on stated…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #119 · Evidence › Journal club · 19 Jul 2026 · 12 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
-
Revisiting: How this community labels and discusses unrefereed work Replied, post #27 · Evidence › Preprints · 17 Jul 2026 · 29 likes Coming back to post #25, because the follow-up matters more than the original answer. Unrefereed work is not worthless. A great deal of it survives review substantially…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #64 · Practice › Dosing & titration · 14 Jul 2026 · 0 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #36 · Start Here › Welcome · 12 Jul 2026 · 32 likes Coming back to post #34, because the follow-up matters more than the original answer. Nothing here requires expertise. The experienced members here got that way by…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #83 · Practice › Interactions · 11 Jul 2026 · 11 likes Metformin: commonly co-administered and relevant to gastrointestinal tolerability. Gastrointestinal side effects can overlap and additive. Taking them separately or…
-
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #15 · Clinical › Comorbidities · 10 Jul 2026 · 0 likes Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #7 · Access › Insurance & coverage · 7 Jul 2026 · 4 likes This follows post #4 rather than contradicting it. Documentation your clinician can provide: letters from clinicians describing why standard treatments have failed or…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #41 · Start Here › Welcome · 25 Jun 2026 · 0 likes post #40 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Preservatives: function, testing, and limits — one year on Replied, post #26 · Pharmacology › Formulation chemistry · 23 Jun 2026 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…